PE20211211A1 - Metodos para potenciar la biodisponibilidad y la exposicion de un abridor de canales de potasio dependientes de voltaje - Google Patents

Metodos para potenciar la biodisponibilidad y la exposicion de un abridor de canales de potasio dependientes de voltaje

Info

Publication number
PE20211211A1
PE20211211A1 PE2020001843A PE2020001843A PE20211211A1 PE 20211211 A1 PE20211211 A1 PE 20211211A1 PE 2020001843 A PE2020001843 A PE 2020001843A PE 2020001843 A PE2020001843 A PE 2020001843A PE 20211211 A1 PE20211211 A1 PE 20211211A1
Authority
PE
Peru
Prior art keywords
potassium channel
bioavailability
enhance
exposure
methods
Prior art date
Application number
PE2020001843A
Other languages
English (en)
Inventor
Gregory N Beatch
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of PE20211211A1 publication Critical patent/PE20211211A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente descripcion se dirige al compuesto modulador alosterico del canal de potasio dependiente de voltaje, N-[4-(6-fluoro-3,4-dihidro-1H-isoquinolin-2-il)-2,6-dimetilfenil]-3,3-dimetilbutanamida (Compuesto A), el cual es util en el tratamiento de enfermedades asociadas con la disfuncion del canal de potasio Kv7.
PE2020001843A 2018-05-11 2019-05-10 Metodos para potenciar la biodisponibilidad y la exposicion de un abridor de canales de potasio dependientes de voltaje PE20211211A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862670253P 2018-05-11 2018-05-11
PCT/US2019/031872 WO2019217924A1 (en) 2018-05-11 2019-05-10 Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener

Publications (1)

Publication Number Publication Date
PE20211211A1 true PE20211211A1 (es) 2021-07-05

Family

ID=66669101

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020001843A PE20211211A1 (es) 2018-05-11 2019-05-10 Metodos para potenciar la biodisponibilidad y la exposicion de un abridor de canales de potasio dependientes de voltaje

Country Status (31)

Country Link
US (2) US11135214B2 (es)
EP (2) EP4279133A3 (es)
JP (1) JP2021523130A (es)
KR (1) KR20210020892A (es)
CN (1) CN112384216A (es)
AU (1) AU2019265002A1 (es)
BR (1) BR112020022713A2 (es)
CA (1) CA3099292A1 (es)
CL (1) CL2020002932A1 (es)
CO (1) CO2020015476A2 (es)
CR (1) CR20200602A (es)
DK (1) DK3790548T3 (es)
EA (1) EA202092720A1 (es)
ES (1) ES2964409T3 (es)
FI (1) FI3790548T3 (es)
GE (1) GEP20237527B (es)
HR (1) HRP20231447T1 (es)
HU (1) HUE064326T2 (es)
LT (1) LT3790548T (es)
MA (1) MA52569B1 (es)
MD (1) MD3790548T2 (es)
MX (1) MX2020012008A (es)
PE (1) PE20211211A1 (es)
PH (1) PH12020551898A1 (es)
PL (1) PL3790548T3 (es)
PT (1) PT3790548T (es)
RS (1) RS64922B1 (es)
SG (1) SG11202011102TA (es)
SI (1) SI3790548T1 (es)
UA (1) UA127229C2 (es)
WO (1) WO2019217924A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3790548T3 (fi) 2018-05-11 2023-11-17 Xenon Pharmaceuticals Inc Menetelmiä jänniteriippuvaisen kaliumkanavan avaajan biosaatavuuden ja eksposition tehostamiseksi
TW202128627A (zh) 2019-10-10 2021-08-01 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
KR20220113411A (ko) * 2019-12-06 2022-08-12 제논 파마슈티칼스 인크. KV7 칼륨 채널 개방제(opener)의 통증 치료를 위한 용도
CA3207191A1 (en) * 2021-02-09 2022-08-18 Simon Neil PIMSTONE Voltage-gated potassium channel opener for use in treating anhedonia
WO2022173853A1 (en) * 2021-02-09 2022-08-18 Xenon Pharmaceuticals Inc. Conjoint therapy for treating seizure disorders
EP4074696A4 (en) * 2021-10-27 2024-01-31 Shanghai Zhimeng Biopharma Inc POTASSIUM CHANNEL REGULATOR COMPOUND, PRODUCTION AND USE THEREOF
CN113698345B (zh) * 2021-10-27 2022-02-01 上海挚盟医药科技有限公司 作为钾通道调节剂的化合物及其制备和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
WO2006130686A2 (en) 2005-06-02 2006-12-07 Schering Corporation Hcv protease inhibitors in combination with food
CA2650853A1 (en) 2006-05-02 2007-11-15 Chris Rundfeldt Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
MX2009002002A (es) * 2006-08-23 2009-07-22 Valeant Pharmaceuticals Int Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potasio.
US10500216B2 (en) 2011-11-18 2019-12-10 Corcept Therapeutics, Inc. Optimizing mifepristone absorption
FI3790548T3 (fi) 2018-05-11 2023-11-17 Xenon Pharmaceuticals Inc Menetelmiä jänniteriippuvaisen kaliumkanavan avaajan biosaatavuuden ja eksposition tehostamiseksi

Also Published As

Publication number Publication date
CR20200602A (es) 2021-03-02
AU2019265002A1 (en) 2020-12-03
EP3790548A1 (en) 2021-03-17
MX2020012008A (es) 2021-04-12
EP4279133A2 (en) 2023-11-22
CN112384216A (zh) 2021-02-19
SI3790548T1 (sl) 2024-02-29
EP4279133A3 (en) 2024-02-21
HUE064326T2 (hu) 2024-03-28
MD3790548T2 (ro) 2024-02-29
PT3790548T (pt) 2023-11-23
MA52569A (fr) 2021-03-17
WO2019217924A1 (en) 2019-11-14
UA127229C2 (uk) 2023-06-14
CO2020015476A2 (es) 2021-01-29
GEP20237527B (en) 2023-08-10
CL2020002932A1 (es) 2021-02-26
FI3790548T3 (fi) 2023-11-17
CA3099292A1 (en) 2019-11-14
RS64922B1 (sr) 2023-12-29
US11135214B2 (en) 2021-10-05
EP3790548B1 (en) 2023-08-23
US20190343823A1 (en) 2019-11-14
HRP20231447T1 (hr) 2024-03-01
MA52569B1 (fr) 2023-11-30
SG11202011102TA (en) 2020-12-30
PL3790548T3 (pl) 2024-03-11
BR112020022713A2 (pt) 2021-02-02
EA202092720A1 (ru) 2021-04-14
PH12020551898A1 (en) 2021-07-12
DK3790548T3 (da) 2023-11-13
JP2021523130A (ja) 2021-09-02
ES2964409T3 (es) 2024-04-05
US20220062266A1 (en) 2022-03-03
LT3790548T (lt) 2024-01-10
KR20210020892A (ko) 2021-02-24

Similar Documents

Publication Publication Date Title
PE20211211A1 (es) Metodos para potenciar la biodisponibilidad y la exposicion de un abridor de canales de potasio dependientes de voltaje
CU20200014A7 (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona
CY1123059T1 (el) Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1
EA201891620A1 (ru) Ингибиторы взаимодействующей с рецептором протеинкиназы 1
CO2020013252A2 (es) Dosificación subcutánea de anticuerpos anti-cd38
TR201908761T4 (tr) Antidll3-antikor-pbd konjugatları ve kullanımları.
EA201892487A1 (ru) Способ получения соединения диарилтиогидантоина
EA201792590A1 (ru) КОНЪЮГАТ АНТИТЕЛА ПРОТИВ ErbB2 И ЛЕКАРСТВЕННОГО СРЕДСТВА И ЕГО КОМПОЗИЦИЯ, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ
EA201790896A1 (ru) Пролекарства фенольных агонистов trpv1
MX2022008479A (es) Combinaciones de brimonidina de dosis baja y usos de las mismas.
CL2020001290A1 (es) Método para el tratamiento de enfermedades gastrointestinales con tradipitant.
BR112017022281A2 (pt) métodos para tratar câncer
EA202091604A1 (ru) Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом
EA202091046A1 (ru) Гербициды на основе пиридин- и пиримидинкарбоксилата и способы их применения
EA202091205A1 (ru) Композиции для терапии гипергликемии и сопутствующих состояний
EA202090691A1 (ru) Лечение заболевания, опосредованного гмк
EA202092823A1 (ru) Новые аминофункционализированные полимеры и способы получения
UY38081A (es) Método para operar con un cajero automático
CL2019002031A1 (es) Moduladores del canal de potasio.
ECSP20082970A (es) Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso
CL2021000797A1 (es) Una ayuda para la deposición de fluidos agrícolas.
AR047716A1 (es) Combinaciones de analepticos y antidepresivos
CL2020000397A1 (es) Formulaciones de anticuerpos inhibitorio para masp-2 de baja viscosidad altamente concentradas, kits, y métodos de tratamiento de sujetos que sufren de síndrome hemolítico atípico.
EA202090333A1 (ru) Фармацевтические комбинации, содержащие антитело к bst1 и аналог цитидина
EA202190699A1 (ru) Альтернативные способы получения тубулизинов и их промежуточных соединений